Non-inferiority study design: Lessons to be learned from cardiovascular trials

European Heart Journal

Volumn 33, Issue 11, 2012, Pages 1318-1324

  Head, Stuart J ^a   Kaul, Sanjay ^b   Bogers, Ad J J C ^a   Kappetein, A Pieter ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Methodology; Non inferiority; Randomized trial; Trial design

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; APIXABAN; DABIGATRAN; NEW DRUG; PACLITAXEL; PLACEBO; RIVAROXABAN; THROMBIN INHIBITOR; WARFARIN;

ANTICOAGULATION; BARE METAL STENT; CARDIOVASCULAR DISEASE; CLINICAL RESEARCH; CLINICAL TRIAL (TOPIC); COMPARATIVE STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DRUG DOSE COMPARISON; DRUG ELUTING STENT; FOLLOW UP; HEART ATRIUM FIBRILLATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; META ANALYSIS (TOPIC); METHODOLOGY; MITRAL VALVE DISEASE; NON INFERIORITY TRIAL (TOPIC); PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZATION; REVIEW; STROKE; THROMBOSIS; TREATMENT OUTCOME;

CARDIOVASCULAR DISEASES; DATA INTERPRETATION, STATISTICAL; ENDPOINT DETERMINATION; FOLLOW-UP STUDIES; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; RISK ASSESSMENT;

EID: 84861821752     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehs099     Document Type: Review

References (27)

1. Lang J, Cetre JC, Picot N, Lanta M, Briantais P, Vital S, Le Mener V, Lutsch C, Rotivel Y. Immunogenicity and safety in adults of a new chromatographically purified Vero-cell rabies vaccine (CPRV): a randomized, double-blind trial with purified Vero-cell rabies vaccine (PVRV). Biologicals 1998;26:299-308. (Pubitemid 29263789)
2. Garattini S, Bertele V. Non-inferiority trials are unethical because they disregard patients' interests. Lancet 2007;370:1875-1877. (Pubitemid 350180009)
3. Kaul S, Diamond GA. Good enough: a primer on the analysis and interpretation of noninferiority trials. Ann Intern Med 2006;145:62-69. (Pubitemid 46780603)
4. D'Agostino RB Sr, Massaro JM, Sullivan LM. Non-inferiority trials: design concepts and issues-the encounters of academic consultants in statistics. Stat Med 2003; 22:169-186. (Pubitemid 36163579)
5. James Hung HM, Wang SJ, Tsong Y, Lawrence J, O'Neil RT. Some fundamental issues with non-inferiority testing in active controlled trials. Stat Med 2003; 22:213-225. (Pubitemid 36163582)
6. Piaggio G, Elbourne DR, Altman DG, Pocock SJ, Evans SJ, Group C. Reporting of noninferiority and equivalence randomized trials: an extension of the CONSORT statement. JAMA 2006;295:1152-1160. (Pubitemid 43352345)
7. Le Henanff A, Giraudeau B, Baron G, Ravaud P. Quality of reporting of noninferiority and equivalence randomized trials. JAMA 2006;295:1147-1151. (Pubitemid 43352344)
8. Feldman T, Foster E, Glower DG, Kar S, Rinaldi MJ, Fail PS, Smalling RW, Siegel R, Rose GA, Engeron E, Loghin C, Trento A, Skipper ER, Fudge T, Letsou GV, Massaro JM, Mauri L, EVEREST II Investigators. Percutaneous repair or surgery for mitral regurgitation. N Engl J Med 2011;364:1395-1406.
9. Park SJ, Kim YH, Park DW, Yun SC, Ahn JM, Song HG, Lee JY, Kim WJ, Kang SJ, Lee SW, Lee CW, Park SW, Chung CH, Lee JW, Lim DS, Rha SW, Lee SG, Gwon HC, Kim HS, Chae IH, Jang Y, Jeong MH, Tahk SJ, Seung KB. Randomized Trial of Stents versus Bypass Surgery for Left Main Coronary Artery Disease. N Engl J Med 2011;364:1718-1727.
10. Serruys P, Morice M, Kappetein A, Colombo A, Holmes DR, Mack MJ, Stahle E, Feldman TE, van den Brand MJ, Bass E, van Dyck N, Leadley K, Dawkins KD, Mohr FW, SYNTAX Investigators. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med 2009;360:961-972.
11. Kaul S, Diamond GA, Weintraub WS. Trials and tribulations of non-inferiority: the ximelagatran experience. J Am Coll Cardiol 2005;46:1986-1995. (Pubitemid 41713579)
12. Smith CR, Leon MB, Mack MJ, Miller DC, Moses JW, Svensson LG, Tuzcu EM, Webb JG, Fontana GP, Makkar RR, Williams M, Dewey T, Kapadia S, Babaliaros V, Thourani VH, Corso P, Pichard AD, Bavaria JE, Herrmann HC, Akin JJ, Anderson WN, Wang D, Pocock SJ, PARTNER Trial Investigators. Transcatheter versus surgical aortic-valve replacement in high-risk patients. N Engl J Med 2011; 364:2187-2198.
13. Leon MB, Smith CR, Mack M, Miller DC, Moses JW, Svensson LG, Tuzcu EM, Webb JG, Fontana GP, Makkar RR, Brown DL, Block PC, Guyton RA, Pichard AD, Bavaria JE, Herrmann HC, Douglas PS, Petersen JL, Akin JJ, Anderson WN, Wang D, Pocock S, PARTNER Trial Investigators. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med 2010;363:1597-1607.
14. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD,Wallentin L, RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-1151.
15. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM, ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883-891.
16. Albers GW, Diener HC, Frison L, Grind M, Nevinson M, Partridge S, Halperin JL, Horrow J, Olsson SB, Petersen P, Vahanian A, SPORTIF Executive Steering Committee for the SPORTIF V Investigators. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. JAMA 2005;293:690-698. (Pubitemid 40220342)
17. Schumi J, Wittes JT. Through the looking glass: understanding non-inferiority. Trials 2011;12:106.
18. Mercado N, Wijns W, Serruys PW, Sigwart U, Flather MD, Stables RH, O'Neill WW, Rodriguez A, Lemos PA, Hueb WA, Gersh BJ, Booth J, Boersma E. One-year outcomes of coronary artery bypass graft surgery versus percutaneous coronary intervention with multiple stenting for multisystem disease: a meta-analysis of individual patient data from randomized clinical trials. J Thorac Cardiovasc Surg 2005;130:512-519. (Pubitemid 41074186)
19. Seung KB, Park DW, Kim YH, Lee SW, Lee CW, Hong MK, Park SW, Yun SC, Gwon HC, Jeong MH, Jang Y, Kim HS, Kim PJ, Seong IW, Park HS, Ahn T, Chae IH, Tahk SJ, Chung WS, Park SJ. Stents versus coronary-artery bypass grafting for left main coronary artery disease. N Engl J Med 2008;358:1781-1792. (Pubitemid 351581190)
20. Correia LC. Stents versus CABG for left main coronary artery disease. N Engl J Med 2011;365:181; author reply 181-182.
21. Mantovani V, Lepore V, Mira A, Berglin E. Non-inferiority randomized trials, an issue between science and ethics: the case of the SYNTAX study. Scand Cardiovasc J 2010;44:321-324.
22. Ellenberg SS, Temple R. Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 2: practical issues and specific cases. Ann Intern Med 2000;133:464-470.
23. Kappetein AP, Feldman TE, Mack MJ, Morice MC, Holmes DR, Stahle E, Dawkins KD, Mohr FW, Serruys PW, Colombo A. Comparison of coronary bypass surgery with drug-eluting stenting for the treatment of left main and/or three-vessel disease: 3-year follow-up of the SYNTAX trial. Eur Heart J 2011; 32:2125-2134.
24. Snapinn SM. Alternatives for discounting in the analysis of noninferiority trials. J Biopharm Stat 2004;14:263-273. (Pubitemid 38715780)
25. Hasselblad V, Kong D. Statistical methods in for comparison to placebo in activecontrolled trials. Drug Inf J 2001;35:435-449. (Pubitemid 32524896)
26. Jones B, Jarvis P, Lewis JA, Ebbutt AF. Trials to assess equivalence: the importance of rigorous methods. BMJ 1996;313:36-39. (Pubitemid 26229889)
27. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L, ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365:981-992.